Two recently published meta-analyses of randomised trial with ivermectin in patients with Covid 19 have shown significant reduction in mortality. Lower levels of inflammatory markers ( d Dimer, CRP and ferritin) have been associated with ivermectin , as also quicker clearance of C19 virus.
Strangely there has hardly been any stir in the Western press; it is difficult to fathom the reasons. Hopefully the Indian press gets more excited.
The 2 trials need exposure, especially considering “breakthrough” infections despite being fully vaccinated against the Delta variant.
It is obvious that more C 19 variants shall keep popping up.
1)Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines
American Journal of Therapeutics 28, e434–e460 (2021)
2) Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection
Published by Oxford University Press on behalf of Infectious Diseases Society of America.
